Multienzyme-immobilized modified polypropylene membrane for an amperometric creatinine biosensor

Electrochemical Creatinine (Bio)Sensors for Point-of-Care Diagnosis of Renal Malfunction and Chronic Kidney Disorders

In the post-pandemic era, point-of-care (POC) diagnosis of diseases is an important research frontier. Modern portable electrochemical (bio)sensors enable the design of POC diagnostics for the identification of diseases and regular healthcare monitoring. Herein, we present a critical review of the electrochemical creatinine (bio)sensors. These sensors either make use of biological receptors such as enzymes or employ synthetic responsive materials, which provide a sensitive interface for creatinine-specific interactions. The characteristics of different receptors and electrochemical devices are discussed, along with their limitations. The major challenges in the development of affordable and deliverable creatinine diagnostics and the drawbacks of enzymatic and enzymeless electrochemical biosensors are elaborated, especially considering their analytical performance parameters. These revolutionary devices have potential biomedical applications ranging from early POC diagnosis of chronic kidney disease (CKD) and other kidney-related illnesses to routine monitoring of creatinine in elderly and at-risk humans.

Trend in creatinine determining methods: Conventional methods to molecular‐based methods

Renal failure (RF) disease is ranked as one of the most prevalent diseases with severe morbidity and mortality. Early diagnosis of RF leads to subsequent control of disease to reduce the poor prognosis. The level of sera creatinine is considered as a significant biomarker for kidney biofunction, which is routinely detected by the Jaffe reaction. The normal range for creatinine in the blood may be 0.84‐1.21 mg/dL. Low accuracy, insufficient sensitivity, explosive and toxicity of picric acid, and pseudo‐interaction with nonspecific elements such as ammonium ions in the Jaffe method lead to the development of various techniques for precise detection of creatinine such as spectroscopic, electrochemical, and chromatography approaches and sensors based on enzymes, molecular imprinted polymer and nanoparticles, etc. Based on previously established results, they are trying to construct sensors with high accuracy, optimum sensitivity, acceptable linear/calibration range, and limit of detection, which are small in size and applicable by the patient him/herself (point‐of‐care testing). By comparing the results of research, a molecularly imprinted electrochemiluminescence‐based sensor with linear/calibration range of 5‐1 mMconcentration of creatinine and the detection limit of 0.5 nM has the best detectable resolution with 2 million measurable points. In this paper, we will review the recently developed methods for measuring creatinine concentration and renal biofunction.

Fabrication of an improved amperometric creatinine biosensor based on enzymes nanoparticles bound to Au electrode

An improved amperometric creatinine biosensor was fabricated that dependent on covalent immobilisation of nanoparticles of creatininase (CANPs), creatinase (CINPs) and sarcosine oxidase (SOxNPs) onto gold electrode (AuE). The CANPs/CINPs/SOxNPs/AuE was characterised by scanning electron microscopy and cyclic voltammetry at various stages. The working electrode exhibited optimal response within 2 s at a potential of 0.6 V, against Ag/AgCl, pH 6.5 and 30 °C. A linear relationship was observed between creatinine concentration range, 0.1-200μM and biosensor response i.e. current in mA, under optimum conditions. Biosensor offered a low detection limit of 0.1 μM with long storage stability. Analytical recoveries of added creatinine in blood sera at 0.5 mM and at 1.0 mM concentrations, were 92.0% and 79.20% respectively. The precision i.e. within and between-batch coefficients of variation were 2.04% and 3.06% respectively. There was a good correlation (R² = 0.99) between level of creatinine in sera, as calculated by the colorimetric method and present electrode. The CANPs/CINPs/SOxNPs/Au electrode was reused 200 times during the period of 180 days, with just 10% loss in its initial activity, while being stored at 4 °C, when not in use.HighlightsPrepared and characterised creatininase (CA), creatinase (CI) sarcosine oxidase (SOx) nanoparticles and immobilised them onto gold electrode (AuE) for fabrication of an improved amperometric creatinine biosensor.The biosensor displayed a limit of detection (LOD) of 0.1 μM with a linear working range of 0.1 μM-200 μM.The biosensor was evaluated and applied to measure elevated creatinine levels in sera from whom suffering from kidney and muscular disorders.The working electrode retained 90% of its initial activity, while being stored dry at 4 ˚C for 180 days.

Sensitive Detection of Serum Creatinine Based on β-Cyclodextrin-Ferrocenylmethanol Modified Screen-printed Electrode

Ferrocenylmethanol (Fc-OH) is included in β-cyclodextrin (β-CD) to form the β-CD-Fc-OH complex by host-guest supramolecular interaction. β-CD dissociates from the β-CD-Fc-OH complex due to the conversion of Fc-OH to Fc⁺-OH under a stimulus of oxidant. In our study, Fc-OH is oxidized after a series of enzymatic reactions of creatinine, which blocks the other means for oxidation of Fc-OH. And the background noise is reduced for testing for serum creatinine (sCr). The chronoamperometry signal for creatinine (with a constant potential -0.3 V vs. Ag/AgCl) increases linearly in the 1 - 1000 μM range, with a limit of detection as low as 0.5 μM. The amperometric potential of -0.3 V greatly prevents the interference of various redox substances in serum. The biosensor was used to test 120 clinical specimens and the results showed a linear correlation with the biochemical analyzer (R² = 0.9885). The biosensor could be applied to clinical trials and offers good prospects for clinical sCr detection.

Biosensing methods for determination of creatinine: A review

Creatinine is a metabolic product of creatine phosphate in muscles, which provides energy to muscle tissues. Creatinine has been considered as indicator of renal function specifically after dialysis, thyroid malfunction and muscle damage. The normal level of creatinine in the serum and its excretion through urine in apparently healthy individuals is 45-140 μM and 0.8-2.0 gm/day respectively. The level of creatinine reaches >1000 μM in serum during renal, thyroid and kidney dysfunction or muscle disorder. A number of conventional methods such as colorimetric, spectrophotometric and chromatographic are available for determination of creatinine. Besides the advantages of being highly sensitive and selective, these methods have some drawbacks like time-consuming, requirement of sample pre-treatment, high cost instrumental set-up and skilled persons to operate. The sensors/biosensors overcome these drawbacks, as these are fast, easy, cost effective and highly sensitive. This review article describes the classification, operating principles, merits and demerits of various creatinine sensors/biosensors, specifically nanomaterials based biosensors. Creatinine biosensors work optimally within 2-900 s, potential range 0.1-1.0 V, pH range 4.0-10.0, temperature range 25-35 °C and had linear range, 0.004-30000 µM for creatinine with the detection limit between 0.01.01 µM and 520 µM. These biosensors measured creatinine level in sera and urine samples and had storage stability between 4 and 390 days, while being stored dry at 4 °C. The future perspective for further improvement and commercialization of creatinine biosensors are discussed.

A new disposable microfluidic electrochemical paper-based device for the simultaneous determination of clinical biomarkers

A new disposable microfluidic electrochemical paper-based device (ePAD) consisting of two spot sensors in the same working electrode for the simultaneous determination of uric acid and creatinine was developed. The spot 1 surface was modified with graphene quantum dots for direct uric acid oxidation and spot 2 surface modified with graphene quantum dots, creatininase and a ruthenium electrochemical mediator for creatinine oxidation. The ePAD was employed to construct an electrochemical sensor (based on square wave voltammetry analysis) for the simultaneous determination of uric acid and creatinine in the 0.010-3.0 µmol L^-1 range. The device showed excellent analytical performance with a very low simultaneous detection limit of 8.4 nmol L^-1 to uric acid and 3.7 nmol L^-1 to creatinine and high selectivity. The ePAD was applied to the rapid and successful determination of those clinical biomarkers in human urine samples.

Assembling Amperometric Biosensors for Clinical Diagnostics

Clinical diagnosis and disease prevention routinely require the assessment ofspecies determined by chemical analysis. Biosensor technology offers several benefits overconventional diagnostic analysis. They include simplicity of use, specificity for the targetanalyte, speed to arise to a result, capability for continuous monitoring and multiplexing,together with the potentiality of coupling to low-cost, portable instrumentation. This workfocuses on the basic lines of decisions when designing electron-transfer-based biosensorsfor clinical analysis, with emphasis on the strategies currently used to improve the deviceperformance, the present status of amperometric electrodes for biomedicine, and the trendsand challenges envisaged for the near future.

Targeted delivery system for juxtacrine signaling growth factor based on rhBMP-2-mediated carrier-protein conjugation

We propose a model of artificial juxtacrine signaling for the controlled release of recombinant human bone morphogenetic protein-2 (rhBMP-2) suitable for guided bone regeneration. A porous three-dimensional scaffold of poly-(lactide-co-glycolide) was fabricated by means of gel molding and particulate leaching. Collagen immobilization onto the scaffold surface was produced by performing photo-induced graft polymerization of acrylic acid, and rhBMP-2 was tethered to the collagenous surface by covalent conjugation. On pharmacokinetic analysis, in vitro enzyme-linked immunosorbent and alkaline phosphatase assays revealed sustained, slow release of rhBMP-2 over 28 days, with a cumulative release of one third of the initial load diffusing out of the scaffold. Conjugation of rhBMP-2 inhibited the free lateral diffusion and internalization of the activated complex of rhBMP-2 and the bone morphogenetic protein receptor. Osteoprogenitor cells were used as bone precursors to determine the expression of biosignaling growth factor in regulating cell proliferation and differentiation. To identify the phenotype of cells seeded on the rhBMP-2-conjugated scaffold, cellular activity was evaluated with scanning electron microscopy and with viability, histological, and immunohistochemical testing. The rhBMP-2-conjugated scaffold prolonged stimulation of intracellular signal proteins in cells. Enhancement of cell growth and differentiation was considered a consequence of juxtacrine signaling transduction. Animal studies of rhBMP-2-containing filling implants showed evidence of resorption and de novo bone formation. The present study revealed the potential of biomimetic constructs with co-immobilized adhesion and growth factors to induce osteoinduction and osteogenesis. Such constructs may be useful as synthetic bone-graft materials in orthopaedic tissue engineering.